IP Library Granted Patent US 10,065,994
Granted Patent B2
US 10,065,994 · App. 14/946,324 · Granted Sep 4, 2018

Norovirus derived immunogenic compositions and methods

Inventors: Ethan Settembre (Lexington, MA); Angelica Medina-Selby (San Francisco, CA); Doris Coit (Petaluma, CA); Philip R. Dormitzer (Weston, MA)
Assignee: Novartis AG
C07K14/005A61K39/12A61K39/295C07K14/08C12N7/00C07K2319/00C12N2770/16022C12N2770/16023
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,065,994
App. No.
14/946,324
Granted
Sep 4, 2018
Kind
B2
Abstract

The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain. The invention also relates to nucleic acids that encode the chimeric VP1 proteins, virus-like particles that contain a chimeric norovirus VP1 protein, and to immunogenic compositions.

Claims (20)

1. A method of producing a chimeric norovirus VP1 protein or norovirus virus like particles (VLPs) comprising the chimeric norovirus VP1 protein, the method comprising

culturing a recombinant host cell comprising a recombinant nucleic acid encoding a chimeric norovirus viral protein 1 (VP1) comprising an S-domain of the VP1 from a first norovirus strain and a P-domain of the VP1, wherein all or a portion of the P-domain is from a second norovirus strain, under conditions suitable for the expression of the recombinant nucleic acid and

obtaining the chimeric VP1 protein or the VLPs from the culture, wherein the VP1 protein has the formula:

A-S-L-P-B

wherein

A and B are independently absent or comprise any desired amino acid sequence;

S is the S-domain of VP1 from a first norovirus strain;

P is a norovirus VP1 P-domain; wherein at least a portion of the P-domain is from a second norovirus strain;

L is absent or a linker peptide selected from the group consisting of

a linker peptide of the VP1 from the first norovirus strain, from the second norovirus strain, or from a third norovirus strain;

a polyglycine linker of formula (Gly)n wherein n=2, 3, 4, 5, 6, 7, 8, 9, 10 or more (SEQ ID NO:5);

a linker of formula (GGGS)n wherein n=1, 2, 3 or 4 (SEQ ID NO:6); and

a charged linker of formula (SRSK)n wherein n=1, 2, 3 or 4 (SEQ ID NO:7).

2. The method of claim 1 , wherein the culturing comprises maintaining the recombinant host cell under conditions suitable for formation of VLPs.

3. The method of claim 1 , further comprising isolating the chimeric norovirus VP1 protein or VLPs from the culture media or the recombinant host cells or from both the culture media and the recombinant host cells.

4. The method of claim 3 , wherein VLPs are isolated.

5. The method of claim 4 , wherein the VLPs are isolated using a sucrose cushion or sucrose gradient.

6. The method of claim 1 , wherein the chimeric norovirus VP1 self-assembles into virus like particles (VLPs).

7. The method of claim 1 , wherein the host cell is selected from the group consisting of insect cells, mammalian cells, avian cells, bacteria, yeast cells, Tetrahymena cells and combinations thereof.

8. The method of claim 1 , wherein the chimeric norovirus VP1 is in the form of at least 50% purified VLPs.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2016
From: SETTEMBRE, ETHAN; MEDINA-SELBY, ANGELICA; COIT, DORIS; DORMITZER, PHILIP
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 039994/0834 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2016
From: NOVARTIS VACCINES AND DIAGNOSTICS, INC
To: NOVARTIS AG
Reel/Frame 039994/0854 →
Continuity (3)
Continuation 13808157
Provisional Application 61361581 · Jul 6, 2010
Related Publication 20160222066A1 · Aug 4, 2016
Cited By (1)
US 12,539,327